Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.34 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.34 |
| ▸ | SQLE | Q14534 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11519285 | 0.88 | RAD52 (0.47) | RAD52CXCR4CXCL12ADH1BADH1A | |
| SCHEMBL11522705 | 0.88 | RAD52 (0.47) | RAD52CXCR4CXCL12ADH1BADH1A | |
| SCHEMBL12991531 | 0.87 | SPHK1 (0.35) | RAD52SQLEDPP4DPP7ALDH1A1 | |
| SCHEMBL4741840 | 0.85 | RAD52 (0.50) | RAD52CXCR4CXCL12ADH1BADH1A | |
| SCHEMBL11522649 | 0.85 | RAD52 (0.50) | RAD52CXCR4CXCL12ADH1BADH1A | |
| SCHEMBL17710342 | 0.85 | RAD52 (0.50) | RAD52CXCR4CXCL12ADH1BADH1A | |
| SCHEMBL18236766 | 0.83 | — | — | |
| SCHEMBL25002482 | 0.77 | SMYD3 (0.36) | ADH1BADH1AALDH1A1 | |
| SCHEMBL20395033 | 0.77 | KDM4E (0.40) | RAD52CXCR4CXCL12DPP4DPP7 | |
| SCHEMBL3298507 | 0.76 | RAD52 (0.52) | RAD52CXCR4CXCL12DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8906844-B2 | Immunomodulatory peptides | BIOGEN IDEC HEMOPHILIA INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | RAD52 2961/4885CXCR4 239/4885CXCL12 574/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | RAD52 2961/4885CXCR4 239/4885CXCL12 574/4885 |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | FCGRT, FCGR3B, FCGR2A | RAD52 3417/4885CXCR4 404/4885CXCL12 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.